Seeking Alpha

Trovagene partners with USC in clinical study of cancer monitoring technology

  • TrovaGene (TROV -0.1%) says it's partnering with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using itss cell-free DNA assays.
  • The study is designed to demonstrate that cell-free DNA obtained from urine is a viable systemic sample for colorectal cancer disease monitoring, which includes measuring therapy response, identifying cancer genomic changes and monitoring disease progression.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector